SGLT2 Inhibitor Effects on AF Recurrence Post-Ablation

168 patients with atrial fibrillation and heart failure were studied in a retrospective cohort, with 83 receiving SGLT2 inhibitors and 85 not. The study, authored by Xueying Gao and last updated in May 2026, also includes a meta-analysis of 7,954 patients from 13 studies. It examines the association between SGLT2 inhibitor use and reduced risk of atrial arrhythmia recurrence and mortality after catheter ablation.

Use Cases

• Modeling risk of atrial fibrillation recurrence based on SGLT2 inhibitor use and atrial fibrosis.
• Analyzing the relationship between SGLT2 inhibitors and cardiac function metrics like left atrial diameter and left ventricular ejection fraction.
• Conducting meta-analyses on the efficacy of SGLT2 inhibitors for post-ablation outcomes in patients with heart failure.

Strengths

• The cohort study includes 168 patients with detailed follow-up data at 12 months.
• The meta-analysis aggregates results from 13 studies involving 7,954 patients, providing a broader evidence base.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the primary dataset is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Retrospective cohort study and systematic meta-analysis.

Freshness

Last updated 2026-05-01 04:16:37; freshness should be verified.